N
NextRNA Therapeutics
Committed to develop the next wave of RNA-targeted therapeutics
About NextRNA Therapeutics
NextRNA Therapeutics, Inc. was a biotechnology firm established in January 2021, which has since ceased operations as of August 2025. The company was co-founded by Chief Executive Officer Dominique Verhelle, Ph.D., MBA, along with Carl Novina, M.D., Ph.D., and Leon Wert Lamas, based on pioneering research from Dr. Novina's lab at the Dana-Farber Cancer Institute. Dr. Verhelle brought over two decades of experience in biopharma and venture capital, including leadership roles at Takeda, Third Rock Ventures, Pfizer, and Celgene, where she focused on epigenetics and drug discovery.
The company's business was centered on the burgeoning field of long non-coding RNAs (lncRNAs), which are RNA molecules that do not code for proteins but are crucial in regulating cellular processes. NextRNA's core strategy was to identify disease-causing interactions between lncRNAs and their associated RNA-binding proteins (RBPs) and then develop selective small molecule drugs to disrupt these pathological connections. This approach offered the optionality to target either the lncRNA itself or the protein it interacts with, aiming to create a new class of therapeutics. The company's proprietary drug discovery engine combined a computational platform, NextMap™, with deep biological expertise to systematically find and validate these novel targets.
NextRNA's primary therapeutic focus areas were oncology and neuroscience, with initial lead programs underway in oncology and immunology. The company's business model relied on venture capital funding and strategic partnerships with larger pharmaceutical companies to advance its pipeline. A major milestone was its public launch in March 2022, backed by $56.1 million raised through a seed round and a Series A financing led by investors like Cobro Ventures and Lightchain Capital. In August 2024, NextRNA entered a significant collaboration with Bayer, potentially worth up to $547 million, to jointly develop two first-in-class small molecule programs in oncology. However, the company ceased operations after facing challenges that included difficult market conditions and a delay in achieving a critical milestone within the Bayer partnership.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Mar 2022 | $47M | $187M | Lightchain Capital · Evans Capital · Jefferies Group · Rivas Capital | ↗ |
| SEEDOther financing | Mar 2022 | $9.3M | $37M | Jefferies Group · Lightchain Capital · Evans Capital · Circle Squared Alternative Investment | ↗ |
Growth signals
Latest recorded traffic for NextRNA Therapeutics is 730 monthly website visits, down 61.6% over the last three months. NextRNA Therapeutics's team declined 40% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
NextRNA Therapeutics in the Cambridge ecosystem
The NextRNA Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- CVCobro Ventures
Series A7 investors entered at this stage
Lightchain-capital
Lightchain Capital
Evans Capital
Jefferies Group- RCRivas Capital
Willett Advisors- CICircle Squared Alternative Investment
Other known investors1 additional known investor
Dana-Farber Cancer Institute
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NextRNA Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NextRNA Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








